DeepMed Research

MELANOMA INSTITUTE AUSTRALIA

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website: http://www.melanoma.org.au

Clinical Trials

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Dabrafenib
Drug: Trametinib
Drug: Pembrolizumab

First Posted Date: 2016-08-08

Last Posted Date: 2023-08-30

Lead Sponsor: Melanoma Institute Australia

Target Recruit Count: 60

Registration Number: NCT02858921

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Drug: Trametinib and / or supportive care
Drug: CDK4/6 and MEK inhibitor
Drug: Matched targeted therapy
Drug: Standard therapy or clinical trial
Drug: Compassionate Access Targeted Therapy

First Posted Date: 2016-01-01

Last Posted Date: 2025-01-07

Lead Sponsor: Melanoma Institute Australia

Target Recruit Count: 1000

Registration Number: NCT02645149

Locations: 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Phase 2

Active, not recruiting

Conditions: Brain Metastases
Melanoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2015-02-27

Last Posted Date: 2024-03-19

Lead Sponsor: Melanoma Institute Australia

Target Recruit Count: 76

Registration Number: NCT02374242

Locations: 🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 1 locations

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2013-10-30

Last Posted Date: 2025-01-23

Lead Sponsor: Melanoma Institute Australia

Target Recruit Count: 35

Registration Number: NCT01972347

Locations: 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy